This site is intended for healthcare professionals
News

Brilinta significantly reduced the rate of the composite of stroke and death in patients who had an acute ischaemic stroke or TIA in the phase III THALES trial.- AstraZeneca

Read time: 1 mins
Last updated:28th Jun 2021
Published:17th Jul 2020
Condition: Stroke
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest